Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Anxiety Disorders

Clinical and regulatory intelligence for Anxiety Disorders with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Assets
3

Relevant assets

FDA →
Neurovalens →
Unichem →

Relevant companies

No related entities indexed yet.

Recent signals(5)

ClinicalAugust 3, 2026

Study Evaluates CO2 Biomarker for Predicting Therapy Response in Anxiety Disorders

A study is assessing the predictive power of CO2 challenge biomarker for response to exposure-based therapy in anxiety disorders.

RegulatoryJuly 27, 2026

FDA Submission Update for Buspirone Hydrochloride by Oxford Pharms

The FDA has received a supplemental application for Buspirone Hydrochloride (ANDA075388) from Oxford Pharms.

RegulatoryJuly 18, 2026

FDA Grants AP Status for Alprazolam ANDA213204 by Unichem

The FDA has granted approval status (AP) for the ANDA213204 application for Alprazolam submitted by Unichem.

ClinicalJuly 5, 2026

Neurovalens Initiates VeNS Trial for Adolescent Anxiety Treatment

Neurovalens Ltd. is conducting a randomized trial to assess the efficacy of Electrical Vestibular Stimulation for Generalized Anxiety Disorder in adolescents.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Buspirone Hydrochloride ANDA075388 by Oxford Pharms

The FDA has granted an Abbreviated Approval (AP) status for the ANDA075388 application for Buspirone Hydrochloride submitted by Oxford Pharms.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Anxiety Disorders →
Mental Health →
Neurology →
Psychiatry →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.